An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China-Reference-Cited by-同舟云学术

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China

Published:2017-07 Issue:29 Volume:96 Page:e7445
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Wu Bin,Liu Maobai,Li Te,Lin Houwen,Zhong Hua

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference35 articles.

1. Chronic myeloid leukaemia;Apperley;Lancet,2015

2. Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China;Wang;Zhonghua Xue Ye Xue Za Zhi,2009

3. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS);Hughes;Blood,2010

4. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management;Jabbour;Am J Hematol,2014

5. A review of the European LeukemiaNet recommendations for the management of CML;Baccarani;Ann Hematol,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China;BMC Health Services Research;2023-06-19

2. Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China;BMC Health Services Research;2022-12-26

3. Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list;BMC Health Services Research;2022-12-03

4. A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia;PharmacoEconomics;2022-09-30

5. Tyrosine kinase inhibitors reduce myeloid-derived suppressor cells in patients with chronic myeloid leukemia with better outcome;The Egyptian Journal of Haematology;2022